Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591224 | 0.87 | FFAR1 (0.56) | ATMPGRFFAR1FFAR4MAPT | |
| SCHEMBL1591137 | 0.87 | PGR (0.50) | ATMPGRFFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL1592072 | 0.84 | PGR (0.55) | ATMPGRFFAR1FFAR4 | |
| SCHEMBL1592197 | 0.82 | RORC (0.51) | PGRFFAR1FFAR4SMN1; SMN2LMNA | |
| SCHEMBL1590907 | 0.82 | PGR (0.58) | ATMPGRFFAR1FFAR4BRAF | |
| SCHEMBL1591669 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAHTTALDH1A1MAPT | |
| SCHEMBL1591259 | 0.79 | ATM (0.55) | ATMSMN1; SMN2LMNAMEN1HPGD | |
| SCHEMBL1592213 | 0.79 | CSF1R (0.43) | ATMPGRFFAR1FFAR4ALDH1A1 | |
| SCHEMBL1591088 | 0.78 | PGR (0.60) | PGRFFAR1FFAR4LMNAHTT | |
| SCHEMBL1591396 | 0.78 | ATM (0.49) | ATMSMN1; SMN2LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | ATM 226/4885PGR 2847/4885FFAR1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.